

Claudia De Lorenzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5360932/publications.pdf>

Version: 2024-02-01

69
papers

1,924
citations

172386

29
h-index

289141

40
g-index

69
all docs

69
docs citations

69
times ranked

2039
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand. <i>Cancers</i> , 2022, 14, 1325. | 1.7 | 14 |
| 2 | Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3466. | 1.8 | 6 |
| 3 | Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC. <i>Cancers</i> , 2022, 14, 121. | 1.7 | 7 |
| 4 | A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5556. | 1.8 | 3 |
| 5 | Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, Galectine-3 and NLRP3-MyD88-chemokine pathways.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14516-e14516. | 0.8 | 0 |
| 6 | Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 11046. | 1.6 | 13 |
| 7 | Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. <i>Cancers</i> , 2021, 13, 2858. | 1.7 | 12 |
| 8 | Long-chain polyphosphates impair SARS-CoV-2 infection and replication. <i>Science Signaling</i> , 2021, 14, . | 1.6 | 27 |
| 9 | Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8562. | 1.8 | 20 |
| 10 | Differential cardiotoxicity of immune checkpoint inhibitors involves dampens fibronectin-EDA, calgranulin, galectine-3, and associated nlrp3 inflammasome-interleukins pathway in preclinical models. <i>European Heart Journal Supplements</i> , 2021, 23, . | 0.0 | 0 |
| 11 | Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. <i>Cancers</i> , 2020, 12, 2204. | 1.7 | 12 |
| 12 | Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. <i>Journal of Personalized Medicine</i> , 2020, 10, 179. | 1.1 | 41 |
| 13 | Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 180. | 3.5 | 38 |
| 14 | Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. <i>Cancers</i> , 2020, 12, 331. | 1.7 | 27 |
| 15 | Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing. <i>Cancers</i> , 2019, 11, 1268. | 1.7 | 38 |
| 16 | Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling. <i>Scientific Reports</i> , 2019, 9, 13125. | 1.6 | 44 |
| 17 | Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>International Journal of Cardiology</i> , 2019, 292, 171-179. | 0.8 | 44 |
| 18 | T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. <i>Journal of Immunotherapy</i> , 2019, 42, 1-10. | 1.2 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. <i>BioMed Research International</i> , 2019, 2019, 1-22. | 0.9 | 9 |
| 20 | A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells. <i>MAbs</i> , 2018, 10, 730-737. | 2.6 | 25 |
| 21 | Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. <i>Frontiers in Physiology</i> , 2018, 9, 38. | 1.3 | 36 |
| 22 | Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. <i>MAbs</i> , 2018, 10, 1-13. | 2.6 | 31 |
| 23 | Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2241-2250. | 1.0 | 26 |
| 24 | Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody. <i>Journal of Immunotherapy</i> , 2017, 40, 117-128. | 1.2 | 7 |
| 25 | Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6785-6794. | 1.0 | 24 |
| 26 | Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e19-e26. | 0.6 | 47 |
| 27 | A Practical Approach for Management of QT Prolongation Induced by Anticancer Drugs. <i>Oncologist</i> , 2016, , . | 1.9 | 1 |
| 28 | Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1124-1131. | 1.4 | 46 |
| 29 | Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. <i>Journal of General Virology</i> , 2016, 97, 82-94. | 1.3 | 16 |
| 30 | A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. <i>Oncotarget</i> , 2016, 7, 87016-87030. | 0.8 | 23 |
| 31 | One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1. <i>BioMed Research International</i> , 2015, 2015, 1-9. | 0.9 | 16 |
| 32 | Human anti-nucleolin recombinant immunoagent for cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9418-9423. | 3.3 | 53 |
| 33 | Effect of ranolazine administered after trastuzumab treatment on cardiotoxicity in mice.. <i>Journal of Clinical Oncology</i> , 2015, 33, 597-597. | 0.8 | 0 |
| 34 | Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. <i>Journal of Biological Chemistry</i> , 2014, 289, 35015-35028. | 1.6 | 17 |
| 35 | Effects of a human compact anti-ErbB2 antibody on gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 107-115. | 2.7 | 6 |
| 36 | Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. <i>European Journal of Heart Failure</i> , 2014, 16, 358-366. | 2.9 | 76 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. <i>Protein Engineering, Design and Selection</i> , 2014, 27, 83-88. | 1.0 | 16 |
| 38 | Ranolazine and prevention of trastuzumab-cardiotoxicity in experimental models.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13508-e13508. | 0.8 | 0 |
| 39 | A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor. <i>Protein Engineering, Design and Selection</i> , 2013, 26, 243-248. | 1.0 | 17 |
| 40 | Effects of a human compact anti-ErbB2 antibody on prostate cancer. <i>Oncology Reports</i> , 2012, 28, 297-302. | 1.2 | 3 |
| 41 | Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. <i>European Journal of Heart Failure</i> , 2012, 14, 130-137. | 2.9 | 77 |
| 42 | Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 595-602. | 1.1 | 56 |
| 43 | Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 511-521. | 1.1 | 43 |
| 44 | A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. <i>British Journal of Cancer</i> , 2011, 104, 1716-1723. | 2.9 | 35 |
| 45 | A novel ErbB2 epitope targeted by human antitumor immunoagents. <i>FEBS Journal</i> , 2011, 278, 1156-1166. | 2.2 | 12 |
| 46 | Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. <i>British Journal of Cancer</i> , 2010, 102, 513-519. | 2.9 | 29 |
| 47 | Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. <i>FASEB Journal</i> , 2009, 23, 3171-3178. | 0.2 | 63 |
| 48 | Human anti-ErbB2 immunoagents as immunoRNases and compact antibodies. <i>FEBS Journal</i> , 2009, 276, 1527-1535. | 2.2 | 19 |
| 49 | Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. <i>FEBS Journal</i> , 2008, 275, 4967-4979. | 2.2 | 33 |
| 50 | A Novel Human Antitumor Dimeric ImmunoRNase. <i>Journal of Immunotherapy</i> , 2008, 31, 440-445. | 1.2 | 13 |
| 51 | From ImmunoToxins to ImmunoRNases. <i>Current Pharmaceutical Biotechnology</i> , 2008, 9, 210-214. | 0.9 | 38 |
| 52 | Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. <i>British Journal of Cancer</i> , 2007, 97, 1354-1360. | 2.9 | 11 |
| 53 | Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. <i>FEBS Letters</i> , 2007, 581, 296-300. | 1.3 | 31 |
| 54 | Biological properties of a human compact anti-ErbB2 antibody. <i>Carcinogenesis</i> , 2005, 26, 1890-1895. | 1.3 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. <i>British Journal of Cancer</i> , 2004, 91, 1200-1204. | 2.9 | 41 |
| 56 | A Fully Human Antitumor ImmunoRNase Selective for ErbB-2-Positive Carcinomas. <i>Cancer Research</i> , 2004, 64, 4870-4874. | 0.4 | 67 |
| 57 | Crystal structure of the dimeric unswapped form of bovine seminal ribonuclease. <i>FEBS Letters</i> , 2003, 554, 105-110. | 1.3 | 25 |
| 58 | A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. <i>FEBS Letters</i> , 2002, 516, 208-212. | 1.3 | 32 |
| 59 | A new human antitumor immunoreagent specific for ErbB2. <i>Clinical Cancer Research</i> , 2002, 8, 1710-9. | 3.2 | 46 |
| 60 | The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. <i>Oncogene</i> , 2001, 20, 599-608. | 2.6 | 57 |
| 61 | Trypsin Sheds Light on the Singular Case of Seminal RNase, a Dimer with Two Quaternary Conformations. <i>Journal of Biological Chemistry</i> , 2000, 275, 8000-8006. | 1.6 | 10 |
| 62 | Thermodynamic Stability of the Two Isoforms of Bovine Seminal Ribonuclease. <i>Biochemistry</i> , 2000, 39, 7964-7972. | 1.2 | 11 |
| 63 | A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7768-7773. | 3.3 | 66 |
| 64 | Crystallization of multiple forms of bovine seminal ribonuclease in the liganded and unliganded state. <i>Journal of Crystal Growth</i> , 1999, 196, 305-312. | 0.7 | 9 |
| 65 | Selective and asymmetric action of trypsin on the dimeric forms of seminal RNase. <i>Protein Science</i> , 1998, 7, 2653-2658. | 3.1 | 6 |
| 66 | Effects of Protein RNase Inhibitor and Substrate on the Quaternary Structures of Bovine Seminal RNase. <i>Biochemistry</i> , 1996, 35, 3880-3885. | 1.2 | 39 |
| 67 | A Study of the Intracellular Routing of Cytotoxic Ribonucleases. <i>Journal of Biological Chemistry</i> , 1995, 270, 17476-17481. | 1.6 | 86 |
| 68 | The antitumor action of seminal ribonuclease and its quaternary conformations. <i>FEBS Letters</i> , 1995, 359, 31-34. | 1.3 | 71 |
| 69 | Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 9 |